Jacqueline M Hirth1, Yu-Li Lin2, Yong-Fang Kuo2, Abbey B Berenson3. 1. Department of Obstetrics and Gynecology and Center for Interdisciplinary Research in Women's Health, University of Texas Medical Branch, 301 University Blvd Rte 0587, Galveston, TX 77555, United States. Electronic address: jmhirth@utmb.edu. 2. Office of Biostatistics, Department of Preventive Medicine and Community Health, University of Texas Medical Branch, 301 University Blvd Rte 0587, Galveston, TX 77555, United States. 3. Department of Obstetrics and Gynecology and Center for Interdisciplinary Research in Women's Health, University of Texas Medical Branch, 301 University Blvd Rte 0587, Galveston, TX 77555, United States.
Abstract
PURPOSE: Little is known about how the number of HPV vaccine doses affect adherence to screening guidelines. This study compared adherence to cervical cancer screening by the number of HPV vaccine doses received by young women and assessed whether the specialty of vaccinating providers affected behavior. METHODS: This retrospective cohort study using administrative insurance claims records included 24,964 19-26year old women who received at least 1 injection of the HPV vaccine between January 2006 and November 2009. Vaccinated young women continuously enrolled in a nationally-representative private insurance plan for 6months prior to and 37months after HPV vaccine administration were included. Logistic regression was used to compare the odds of Papanicolaou (Pap) testing 3years after vaccine initiation by number of vaccine doses and provider type. RESULTS: In this sample, 79.3% had a Pap test 3years following vaccine initiation. Receiving 1 (aOR: 0.60, 95% CI 0.55-0.65) or 2 (aOR: 0.80, 95% CI 0.74-0.87) doses was associated with decreased odds of Pap testing compared to 3 doses. Many young women in our sample (16.5%) were diagnosed with cervical dysplasia prior to HPV vaccination. Patients vaccinated by non-obstetrician/gynecologists were less likely to get a Pap test following vaccination. CONCLUSIONS: Women who received 1 or 2 doses of the HPV vaccine were less likely than those who received 3 doses to be screened for cervical cancer 3years following vaccine initiation. Pediatricians and primary care physicians should convey the importance of initiating and continuing screening to HPV vaccinated patients.
PURPOSE: Little is known about how the number of HPV vaccine doses affect adherence to screening guidelines. This study compared adherence to cervical cancer screening by the number of HPV vaccine doses received by young women and assessed whether the specialty of vaccinating providers affected behavior. METHODS: This retrospective cohort study using administrative insurance claims records included 24,964 19-26year old women who received at least 1 injection of the HPV vaccine between January 2006 and November 2009. Vaccinated young women continuously enrolled in a nationally-representative private insurance plan for 6months prior to and 37months after HPV vaccine administration were included. Logistic regression was used to compare the odds of Papanicolaou (Pap) testing 3years after vaccine initiation by number of vaccine doses and provider type. RESULTS: In this sample, 79.3% had a Pap test 3years following vaccine initiation. Receiving 1 (aOR: 0.60, 95% CI 0.55-0.65) or 2 (aOR: 0.80, 95% CI 0.74-0.87) doses was associated with decreased odds of Pap testing compared to 3 doses. Many young women in our sample (16.5%) were diagnosed with cervical dysplasia prior to HPV vaccination. Patients vaccinated by non-obstetrician/gynecologists were less likely to get a Pap test following vaccination. CONCLUSIONS:Women who received 1 or 2 doses of the HPV vaccine were less likely than those who received 3 doses to be screened for cervical cancer 3years following vaccine initiation. Pediatricians and primary care physicians should convey the importance of initiating and continuing screening to HPV vaccinated patients.
Keywords:
Cervical intraepithelial neoplasia; Health care providers; Human papillomavirus; Papanicolaou smear; Papanicolaou test; Papillomavirus vaccines
Authors: Debbie Saslow; Diane Solomon; Herschel W Lawson; Maureen Killackey; Shalini L Kulasingam; Joanna Cain; Francisco A R Garcia; Ann T Moriarty; Alan G Waxman; David C Wilbur; Nicolas Wentzensen; Levi S Downs; Mark Spitzer; Anna-Barbara Moscicki; Eduardo L Franco; Mark H Stoler; Mark Schiffman; Philip E Castle; Evan R Myers Journal: CA Cancer J Clin Date: 2012-03-14 Impact factor: 508.702
Authors: Susan Hariri; Michelle L Johnson; Nancy M Bennett; Heidi M Bauer; Ina U Park; Sean Schafer; Linda M Niccolai; Elizabeth R Unger; Lauri E Markowitz Journal: Cancer Date: 2015-06-22 Impact factor: 6.860
Authors: Stan L Block; Terry Nolan; Carlos Sattler; Eliav Barr; Katherine E D Giacoletti; Colin D Marchant; Xavier Castellsagué; Steven A Rusche; Suzanne Lukac; Janine T Bryan; Paul F Cavanaugh; Keith S Reisinger Journal: Pediatrics Date: 2006-11 Impact factor: 7.124
Authors: Allan Hildesheim; Rolando Herrero; Sholom Wacholder; Ana C Rodriguez; Diane Solomon; M Concepcion Bratti; John T Schiller; Paula Gonzalez; Gary Dubin; Carolina Porras; Silvia E Jimenez; Douglas R Lowy Journal: JAMA Date: 2007-08-15 Impact factor: 56.272
Authors: Chun Chao; Michael J Silverberg; Tracy A Becerra; Douglas A Corley; Christopher D Jensen; Qiaoling Chen; Virginia P Quinn Journal: Am J Obstet Gynecol Date: 2016-10-14 Impact factor: 8.661